Consulting group PwC recently released a paper titled Top Health Industry Issues of 2017: A Year of Uncertainty and Opportunity which discusses "adapting for value, innovating for value and building for value". A key trend in the 'build for value' category is new partnerships and collaborations.
No better example of this concept in action locally in RTP is GlaxoSmithKline's partnership with Google parent Alphabet's Life Sciences division, Verily, to form Galvani Bioelectronics.

No better example of this concept in action locally in RTP is GlaxoSmithKline's partnership with Google parent Alphabet's Life Sciences division, Verily, to form Galvani Bioelectronics. Galvani's mission is to research and develop systems that use electrical signals in the human body to offset diseases. Formed in August 2016, the company will invest over $700M in the next seven years to create miniaturized, implantable devices that can modify irregular or altered electrical nerve signals that occur in many chronic illnesses including type 2 diabetes, arthritis and asthma.

How do two giants in their respective industries partner to successfully produce these life-enhancing devices? What are the challenges and how have the companies addressed them? Come learn from Adam Roth, founding member of the Galvani joint venture and leader of its Business Development activities, as he shares progress and insights.

What Attendees Will Learn

Nature and scope of the GSK/Alphabet alliance

Given more simple options for collaboration available, why a joint venture chosen as the best path forward

Critical success factors for the partnership

How inherent cultural differences between biopharma and high tech are being addressed

Best practices and lessons learned that attendees may consider for their alliance situations

Adam Roth, Director and Head of Business Development & Operations, Galvani